Search Results for: Clinical Roundup
-
Akebia's $41M Cash Infusion Boosts Anemia Drug Work
The financing is expected to fund the lead program to clinical proof of concept for at least one hearing disorder indication. (See BioWorld Today, Aug. 23, 2011By Catherine Shaffer | BioWorld Today | Wednesday, June 5, 2013 -
Clinic Roundup
The Clinical Global Impression-Change (CGI-C) rating, a subjective physician-completed overall improvement scale, showed that at one and two weeks of treatment, 88 percent and 76 percent of subjects improved on N05 vs. 27 percent and 39 percent, respectively, on placebo (p < 0.001, p = 0.0016, respectively...No safety concerns relating to any of the aforementioned products have been identified in any preclinical and clinical data generated to date and there is no reason to believe that theBioWorld Today | Tuesday, June 4, 2013 -
ASCO Roundup
Data from an ongoing Phase I/II study confirmed clinical evidence of the antitumor activity at multiple dose levels in patients with anaplastic lymphoma kinase-positive NSCLC, including brain metastases, and initial clinical evidence of antitumor activity in patients with EGFR receptor mutation NSCLC. (See BioWorld Today, Dec. 17, 2012...and the clinical benefit response rate was 82 percentBioWorld Today | Tuesday, June 4, 2013 -
Same Record? Adcoms to Hear Avandia Data 3rd Time
But this time, they'll be listening to a version conducted by the Duke Clinical Research Institute (DCRI), which was hired by GSK to satisfy the FDA's 2010 demand for an independent readjudication of the CV safety results from the unblinded trial as a condition for allowing the drug to remain on the market for a restricted group of patients...The committees also will discuss how the readjudicated data should be weighed in the overall consideration of CV risk with Avandia and whether additionalBy Mari Serebrov | BioWorld Today | Tuesday, June 4, 2013 -
Clinic Roundup
The study was presented in an oral session at the 53rd Annual New Clinical Drug Evaluation Unit meeting in Hollywood, Fla...Virttu Biologics Ltd., of Glasgow, Scotland, said an on-going clinical study in the U.SBioWorld Today | Monday, June 3, 2013 -
Clinic Roundup
PharmAthene Inc., of Annapolis, Md., said the FDA lifted the clinical hold placed on a proposed Phase II study of SparVax, a next-generation recombinant anthrax vaccine...In a letter to the company, the FDA acknowledged that PharmAthene had satisfactorily addressed all of the agency's clinical hold issues and that the hold had been lifted, effective immediatelyBioWorld Today | Friday, May 31, 2013 -
Pharma: Clinic Roundup
The first-in-man trial will be undertaken by the National Institute of Health Research Experimental Cancer Medicine Centre, based at the Northern Institute of Cancer Research at Newcastle University, as well as at least one other clinical centerBioWorld Today | Friday, May 31, 2013 -
MCMs Moving Forward, but Pediatric Gap a Concern
The draft reflects changes in the standard of care that have occurred over the past 15 years and provides guidance on clinical trial design...It addresses such areas as limiting the use of a placebo, using an active comparator for safety and efficacy trials, designing dosing regimens, establishing efficacy, developing drug-device combination products and using efficacy endpoints such as clinical remission and prevention of structural damage progression...The agency will accept comments on the draftBy Mari Serebrov | BioWorld Today | Friday, May 31, 2013 -
Clinic Roundup
The company is exploring the best options for a new clinical study with higher doses of amitifadine in that populationBioWorld Today | Thursday, May 30, 2013 -
Clinic Roundup
Those results were presented at the New Clinical Drug Evaluation Unit meeting in Hollywood, Fla...Omeros Corp., of Seattle, said it filed a clinical trial application with European regulators to initiate clinical trials of OMS721, its lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2, or MASP-2, programBioWorld Today | Wednesday, May 29, 2013 -
Prosensa Leads More Biotechs into IPO Parade
Prosensa, based in Leiden, the Netherlands, has methodically moved two exon-skipping antisense oligonucleotide drugs into clinical development in Duchenne's muscular dystrophy (DMD) and has three preclinical assets lined up behind them...Although the parent company's Microcyn wound care technology has been widely studied and translated into multiple products, the new formulation will require a full complement of clinical studies, he said...Since we're not going to have clinical data at the time weBy Marie Powers | BioWorld Today | Wednesday, May 29, 2013 -
Taking a Hollywood Cue, Will Congress Remake a Classic?
The government does not match the experience, expertise, clinical knowledge and infrastructure that an ExpressScripts or UnitedHealthcare brings to the negotiating table," he continued...News of the ruling boosted PharmAthene shares (NYSE Amex:PIP), which closed at $2.03 Tuesday, up 43 cents, or 27 percent.By Mari Serebrov | BioWorld Today | Wednesday, May 29, 2013 -
Clinic Roundup
The agency, however, strongly recommended that Adherex consider other larger clinical trial design alternatives...Adherex said, in light of its current resources, it would take the FDA's recommendations into consideration as it reviews its clinical optionsBioWorld Today | Tuesday, May 28, 2013 -
Jennerex Plucks $21.6M Private Placement; Is IPO Up Next?
The San Francisco-based company said proceeds, raised exclusively from existing shareholders and partner companies, will advance the clinical development of Pexa-Vec in HCC and in the follow-on indication of refractory colorectal cancer...The company said proceeds will be used for general corporate purposes, including clinical trial expenses and additional regulatory efforts related to erectile dysfunction drug Vitaros (alprostadil 0.3 percent topical cream) and female sexual dysfunction candidateBy Marie Powers | BioWorld Today | Friday, May 24, 2013 -
Pharma: Clinic Roundup
Results of the PROLASTIN-C SPARK study, a multidose pharmacokinetic clinical trial, were presented at the annual meeting of the American Thoracic Society in PhiladelphiaBioWorld Today | Thursday, May 23, 2013 -
Clinic Roundup
The study is being sponsored by the Alliance for Clinical Trials in Oncology, a cooperative group of the National Cancer Institute (NCI...In the trial, aldoxorubicin showed prolonged clinical activity, including partial tumor response, in two subjects with small-cell lung cancer who had failed other therapies...Promedior Inc., of Lexington, Mass., presented data from a clinical study of PRM-151 at the American Thoracic Society Conference in PhiladelphiaBioWorld Today | Thursday, May 23, 2013 -
IPOpalooza Continues with Portola's $122M Offering
Net proceeds will support the launch of Linzess (linaclotide) in the U.S., and fund development to strengthen the clinical profile of Linzess and expand the product label...The company's platform technology is designed to improve drug delivery into internal body cavities.By Catherine Shaffer | BioWorld Today | Thursday, May 23, 2013 -
More Transparency Hasn't Translated into Import Safety
959, biologics may only be compounded from an approved biologic for a patient for whom the drug produces a clinical benefit, upon receipt of a prescription or medical order...A Medicare beneficiary pays an average cost of $11 for one treatment of compounded bevacizumab compared with about $400 per dose of the approved AMD drugs, the group said. (See BioWorld Today, March 26, 2013.)By Mari Serebrov | BioWorld Today | Thursday, May 23, 2013 -
Financings Roundup
Funds will be used to support ongoing and new clinical trials and development and commercialization of Parkinson's psychosis drug pimavanserin and for general corporate purposes...and to fund linaclotide development opportunities to strengthen the clinical profile of Linzess and expand the product label for additional populations and indications...Net proceeds are expected to total about $37.7 million and will be used to fund clinical trials of SFP, an iron compound for hemodialysis patients, and forBioWorld Today | Wednesday, May 22, 2013 -
Clinic Roundup
Clinical improvements were seen in all patients with reductions in median stool frequency from 23 to 14 per week (p = 0.03) and an improvement in the median Bristol Stool Form Scale assessing stool type from 5.515 to 4.34 (p = 0.05...Marina Biotech Inc., of Bothell, Wash., said licensee Mirna Therapeutics Inc., of Austin, Texas, has begun a Phase I study of MRX34, the first miRNA to advance into a human clinical trial for cancer...Interim data from that study were reported earlier and full data areBioWorld Today | Tuesday, May 21, 2013
Category
Current Filters
- xNOT State of the Industry Report
Related Keywords
Categories
- x BioWorld Today (2616)
- x BioWorld International (51)
- x Bio Perspectives (4)
- x BioWorld Insight (2)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.